Celldex Selling And Marketing Expenses vs Total Operating Expenses Analysis

CLDX Stock

USD 26.70 0.31 1.15%

Celldex Therapeutics financial indicator trend analysis is way more than just evaluating Celldex Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Celldex Therapeutics is a good investment. Please check the relationship between Celldex Therapeutics Selling And Marketing Expenses and its Total Operating Expenses accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.

Selling And Marketing Expenses vs Total Operating Expenses

Selling And Marketing Expenses vs Total Operating Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Celldex Therapeutics Selling And Marketing Expenses account and Total Operating Expenses. At this time, the significance of the direction appears to have weak relationship.

The correlation between Celldex Therapeutics' Selling And Marketing Expenses and Total Operating Expenses is 0.39. Overlapping area represents the amount of variation of Selling And Marketing Expenses that can explain the historical movement of Total Operating Expenses in the same time period over historical financial statements of Celldex Therapeutics, assuming nothing else is changed. The correlation between historical values of Celldex Therapeutics' Selling And Marketing Expenses and Total Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling And Marketing Expenses of Celldex Therapeutics are associated (or correlated) with its Total Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Operating Expenses has no effect on the direction of Selling And Marketing Expenses i.e., Celldex Therapeutics' Selling And Marketing Expenses and Total Operating Expenses go up and down completely randomly.

Correlation Coefficient

0.39

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Selling And Marketing Expenses

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most indicators from Celldex Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Celldex Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.At this time, Celldex Therapeutics' Tax Provision is fairly stable compared to the past year. Enterprise Value is likely to rise to about 1.8 B in 2024, whereas Selling General Administrative is likely to drop slightly above 29.4 M in 2024.

	2023	2024 (projected)
Extraordinary Items	17.2M	15.3M
Reconciled Depreciation	2.9M	3.1M

Extraordinary Items Reconciled Depreciation

Celldex Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Net Receivables	Non Currrent Assets Other	Inventory	Accounts Payable	Short Long Term Debt Total	Short Term Debt	Common Stock Total Equity	Common Stock	Intangible Assets
Total Assets		0.75	0.79	0.98	0.28	-0.43	-0.67	0.39	0.21	0.94	0.69	0.12	0.42	0.8	0.33	0.83	0.94	0.36	-0.04	0.14	0.73	-0.27	0.03	0.39	0.39	0.19
Other Current Liab	0.75		0.67	0.69	0.29	-0.34	-0.46	0.3	0.36	0.63	0.48	0.37	0.29	0.56	0.48	0.59	0.63	0.45	-0.03	-0.01	0.59	-0.1	0.0	0.3	0.3	0.52
Total Current Liabilities	0.79	0.67		0.7	0.71	-0.29	-0.38	0.28	0.51	0.62	0.27	0.44	0.36	0.49	0.66	0.51	0.62	0.41	0.35	0.06	0.61	0.06	0.36	0.67	0.67	0.47
Total Stockholder Equity	0.98	0.69	0.7		0.16	-0.43	-0.69	0.4	0.05	0.98	0.76	-0.05	0.4	0.82	0.16	0.87	0.98	0.31	-0.17	0.2	0.75	-0.32	-0.07	0.27	0.27	0.03
Property Plant And Equipment Net	0.28	0.29	0.71	0.16		-0.38	0.23	0.41	0.63	0.06	-0.42	0.6	0.1	-0.15	0.73	-0.1	0.06	0.08	0.64	-0.08	0.11	0.37	0.6	0.75	0.75	0.53
Net Debt	-0.43	-0.34	-0.29	-0.43	-0.38		-0.07	-0.99	-0.05	-0.42	0.06	0.02	0.02	-0.05	-0.09	-0.05	-0.42	0.03	0.05	-0.07	-0.23	0.3	0.13	-0.39	-0.39	0.03
Retained Earnings	-0.67	-0.46	-0.38	-0.69	0.23	-0.07		0.11	-0.05	-0.65	-0.87	0.04	-0.51	-0.98	-0.06	-0.75	-0.66	-0.6	0.21	0.22	-0.56	0.33	0.13	0.22	0.22	-0.08
Cash	0.39	0.3	0.28	0.4	0.41	-0.99	0.11		0.05	0.38	-0.1	-0.02	-0.04	0.01	0.09	0.01	0.38	-0.07	-0.05	0.09	0.18	-0.21	-0.05	0.39	0.39	-0.05
Non Current Assets Total	0.21	0.36	0.51	0.05	0.63	-0.05	-0.05	0.05		-0.14	-0.26	0.96	0.18	0.04	0.95	-0.1	-0.13	0.29	0.68	-0.25	-0.05	0.23	0.56	0.67	0.67	0.87
Cash And Short Term Investments	0.94	0.63	0.62	0.98	0.06	-0.42	-0.65	0.38	-0.14		0.78	-0.22	0.35	0.79	-0.01	0.87	1.0	0.25	-0.28	0.24	0.75	-0.36	-0.17	0.16	0.16	-0.12
Common Stock Shares Outstanding	0.69	0.48	0.27	0.76	-0.42	0.06	-0.87	-0.1	-0.26	0.78		-0.33	0.42	0.9	-0.22	0.9	0.79	0.33	-0.52	0.14	0.66	-0.31	-0.27	-0.28	-0.28	-0.19
Non Current Liabilities Total	0.12	0.37	0.44	-0.05	0.6	0.02	0.04	-0.02	0.96	-0.22	-0.33		0.16	-0.06	0.96	-0.18	-0.22	0.24	0.7	-0.34	-0.16	0.23	0.49	0.62	0.61	0.95
Other Current Assets	0.42	0.29	0.36	0.4	0.1	0.02	-0.51	-0.04	0.18	0.35	0.42	0.16		0.49	0.26	0.53	0.37	0.16	0.19	-0.2	0.57	-0.17	0.02	0.07	0.07	0.22
Other Stockholder Equity	0.8	0.56	0.49	0.82	-0.15	-0.05	-0.98	0.01	0.04	0.79	0.9	-0.06	0.49		0.08	0.83	0.79	0.57	-0.22	-0.11	0.66	-0.34	-0.13	-0.11	-0.11	0.06
Total Liab	0.33	0.48	0.66	0.16	0.73	-0.09	-0.06	0.09	0.95	-0.01	-0.22	0.96	0.26	0.08		-0.01	0.0	0.28	0.7	-0.27	0.04	0.21	0.53	0.72	0.72	0.91
Property Plant And Equipment Gross	0.83	0.59	0.51	0.87	-0.1	-0.05	-0.75	0.01	-0.1	0.87	0.9	-0.18	0.53	0.83	-0.01		0.88	0.2	-0.35	0.31	0.77	-0.16	-0.07	-0.01	0.0	-0.06
Total Current Assets	0.94	0.63	0.62	0.98	0.06	-0.42	-0.66	0.38	-0.13	1.0	0.79	-0.22	0.37	0.79	0.0	0.88		0.26	-0.28	0.23	0.75	-0.36	-0.17	0.16	0.16	-0.11
Net Receivables	0.36	0.45	0.41	0.31	0.08	0.03	-0.6	-0.07	0.29	0.25	0.33	0.24	0.16	0.57	0.28	0.2	0.26		0.28	-0.51	0.33	-0.2	0.08	-0.03	-0.02	0.29
Non Currrent Assets Other	-0.04	-0.03	0.35	-0.17	0.64	0.05	0.21	-0.05	0.68	-0.28	-0.52	0.7	0.19	-0.22	0.7	-0.35	-0.28	0.28		-0.47	-0.15	0.06	0.45	0.55	0.55	0.59
Inventory	0.14	-0.01	0.06	0.2	-0.08	-0.07	0.22	0.09	-0.25	0.24	0.14	-0.34	-0.2	-0.11	-0.27	0.31	0.23	-0.51	-0.47		0.3	0.1	-0.06	0.26	0.27	-0.43
Accounts Payable	0.73	0.59	0.61	0.75	0.11	-0.23	-0.56	0.18	-0.05	0.75	0.66	-0.16	0.57	0.66	0.04	0.77	0.75	0.33	-0.15	0.3		-0.32	-0.24	0.19	0.2	-0.06
Short Long Term Debt Total	-0.27	-0.1	0.06	-0.32	0.37	0.3	0.33	-0.21	0.23	-0.36	-0.31	0.23	-0.17	-0.34	0.21	-0.16	-0.36	-0.2	0.06	0.1	-0.32		0.8	0.07	0.06	0.19
Short Term Debt	0.03	0.0	0.36	-0.07	0.6	0.13	0.13	-0.05	0.56	-0.17	-0.27	0.49	0.02	-0.13	0.53	-0.07	-0.17	0.08	0.45	-0.06	-0.24	0.8		0.39	0.39	0.36
Common Stock Total Equity	0.39	0.3	0.67	0.27	0.75	-0.39	0.22	0.39	0.67	0.16	-0.28	0.62	0.07	-0.11	0.72	-0.01	0.16	-0.03	0.55	0.26	0.19	0.07	0.39		1.0	0.45
Common Stock	0.39	0.3	0.67	0.27	0.75	-0.39	0.22	0.39	0.67	0.16	-0.28	0.61	0.07	-0.11	0.72	0.0	0.16	-0.02	0.55	0.27	0.2	0.06	0.39	1.0		0.45
Intangible Assets	0.19	0.52	0.47	0.03	0.53	0.03	-0.08	-0.05	0.87	-0.12	-0.19	0.95	0.22	0.06	0.91	-0.06	-0.11	0.29	0.59	-0.43	-0.06	0.19	0.36	0.45	0.45

Click cells to compare fundamentals

Celldex Therapeutics Account Relationship Matchups

Celldex Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	122.9M	235.8M	444.7M	352.7M	465.6M	488.9M
Other Current Liab	2.0M	10.5M	11.8M	12.4M	24.4M	25.6M
Total Current Liabilities	11.6M	14.2M	16.5M	18.6M	31.1M	32.7M
Total Stockholder Equity	94.0M	209.4M	419.5M	326.2M	429.2M	450.6M
Property Plant And Equipment Net	4.0M	3.8M	3.6M	3.7M	6.6M	5.7M
Net Debt	(7.6M)	(40.4M)	(36.1M)	(25.4M)	(32.3M)	(33.9M)
Retained Earnings	(1.0B)	(1.1B)	(1.1B)	(1.3B)	(1.4B)	(1.3B)
Cash	11.2M	43.8M	39.1M	29.4M	34.8M	31.5M
Non Current Assets Total	56.2M	38.0M	33.8M	35.0M	33.9M	31.0M
Cash And Short Term Investments	64.4M	194.4M	408.3M	305.0M	423.6M	444.8M
Common Stock Shares Outstanding	14.5M	29.6M	42.9M	46.9M	48.4M	50.9M
Liabilities And Stockholders Equity	122.9M	235.8M	444.7M	352.7M	465.6M	488.9M
Non Current Liabilities Total	17.3M	12.3M	8.7M	7.9M	5.3M	5.1M
Other Current Assets	2.3M	1.6M	2.4M	12.4M	5.5M	2.8M
Other Stockholder Equity	1.1B	1.3B	1.6B	1.6B	1.8B	1.9B
Total Liab	28.9M	26.5M	25.2M	26.5M	36.5M	25.7M
Property Plant And Equipment Gross	7.5M	7.3M	27.6M	29.4M	29.0M	30.5M
Total Current Assets	66.7M	197.8M	410.8M	317.7M	431.7M	453.3M
Accumulated Other Comprehensive Income	2.6M	2.6M	1.9M	1.3M	3.3M	3.5M
Net Receivables	1.0M	1.8M	172K	347K	2.6M	2.8M
Inventory	(1.0M)	(1.8M)	(172K)	(347K)	1.0	0.95
Accounts Payable	1.2M	1.0M	1.2M	3.3M	3.5M	3.7M
Short Long Term Debt Total	3.7M	3.5M	3.0M	4.0M	2.5M	4.6M
Short Term Debt	1.9M	2.7M	3.5M	2.9M	3.2M	2.9M
Common Stock Total Equity	12K	17K	40K	47K	54.1K	65.1K
Common Stock	12K	17K	40K	47K	56K	64.5K
Intangible Assets	52.2M	34.2M	30.3M	31.3M	27.2M	34.2M
Current Deferred Revenue	2.5M	6.5M	8.5M	12M	10.8M	10.3M
Other Liab	15.6M	10.1M	7.4M	5.3M	6.1M	5.8M
Property Plant Equipment	4.0M	7.3M	6.5M	7.7M	7.0M	7.2M
Short Term Investments	53.2M	150.6M	369.1M	275.5M	388.8M	408.2M
Net Tangible Assets	45.3M	178.7M	392.3M	299.0M	343.9M	361.1M
Retained Earnings Total Equity	(962.4M)	(1.0B)	(1.1B)	(1.1B)	(1.0B)	(1.1B)
Capital Surpluse	1.1B	1.1B	1.3B	1.6B	1.8B	1.0B
Non Current Liabilities Other	17.3M	10.1M	7.4M	5.3M	4.4M	4.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Celldex Stock Analysis

When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Celldex Selling And Marketing Expenses vs Total Operating Expenses Analysis

Selling And Marketing Expenses vs Total Operating Expenses

Selling And Marketing Expenses vs Total Operating Expenses Correlation Analysis

Correlation Coefficient

Selling And Marketing Expenses

Total Operating Expenses

Celldex Therapeutics fundamental ratios Correlations

Celldex Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Celldex Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Celldex Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Total Stockholder Equity	+ 0.98	Total Assets
Cash And Short Term Investments	+ 0.98	Total Stockholder Equity
Total Current Assets	+ 0.98	Total Stockholder Equity
Non Current Liabilities Total	+ 0.96	Non Current Assets Total

Cash	- 0.99	Net Debt
Other Stockholder Equity	- 0.98	Retained Earnings
Common Stock Shares Outstanding	- 0.87	Retained Earnings
Property Plant And Equipment Gross	- 0.75	Retained Earnings
Retained Earnings	- 0.69	Total Stockholder Equity
Retained Earnings	- 0.67	Total Assets